H.B. 77

1

CONTROLLED SUBSTANCES AMENDMENTS
2 2000 GENERAL SESSION
3 STATE OF UTAH
4 Sponsor: Ron Bigelow
5 AN ACT RELATING TO CRIMINAL LAW AND CONTROLLED SUBSTANCES;
6 AMENDING THE SCHEDULE OF CONTROLLED SUBSTANCES TO INCLUDE GHB;
7 SCHEDULING KETAMINE; AND CHANGING THE SCHEDULE OF ROHYPNOL.
8 This act affects sections of Utah Code Annotated 1953 as follows:
9 AMENDS:
10 58-37-4, as last amended by Chapter 283, Laws of Utah 1998
11 Be it enacted by the Legislature of the state of Utah:
12 Section 1. Section 58-37-4 is amended to read:
13 58-37-4. Schedules of controlled substances -- Schedules I through V -- Findings
14 required -- Specific substances included in schedules.
15 (1) There are established five schedules of controlled substances known as Schedules I,
16 II, III, IV, and V which shall consist of substances listed in this section.
17 (2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by the
18 official name, common or usual name, chemical name, or brand name designated:
19 (a) Schedule I:
20 (i) Unless specifically excepted or unless listed in another schedule, any of the following
21 opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when
22 the existence of the isomers, esters, ethers, and salts is possible within the specific chemical
23 designation:
24 (A) Acetyl-alpha-methylfentanyl
25 (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
26 (B) Acetylmethadol;
27 (C) Allylprodine;

28 (D) Alphacetylmethadol, except levo-alphacetylmethadol also known as
29 levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;
30 (E) Alphameprodine;
31 (F) Alphamethadol;
32 (G) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]
33 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N- propanilido) piperidine);
34 (H) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-
35 piperidinyl]-N-phenylpropanamide);
36 (I) Benzethidine;
37 (J) Betacetylmethadol;
38 (K) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
39 piperidinyl]-N-phenylpropanamide);
40 (L) Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2-
41 phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;
42 (M) Betameprodine;
43 (N) Betamethadol;
44 (O) Betaprodine;
45 (P) Clonitazene;
46 (Q) Dextromoramide;
47 (R) Diampromide;
48 (S) Diethylthiambutene;
49 (T) Difenoxin;
50 (U) Dimenoxadol;
51 (V) Dimepheptanol;
52 (W) Dimethylthiambutene;
53 (X) Dioxaphetyl butyrate;
54 (Y) Dipipanone;
55 (Z) Ethylmethylthiambutene;
56 (AA) Etonitazene;
57 (BB) Etoxeridine;
58 (CC) Furethidine;

59 (DD) Hydroxypethidine;
60 (EE) Ketobemidone;
61 (FF) Levomoramide;
62 (GG) Levophenacylmorphan;
63 (HH) Morpheridine;
64 (II) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
65 (JJ) Noracymethadol;
66 (KK) Norlevorphanol;
67 (LL) Normethadone;
68 (MM) Norpipanone;
69 (NN) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4- piperidinyl]
70 propanamide;
71 (OO) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
72 (PP) Phenadoxone;
73 (QQ) Phenampromide;
74 (RR) Phenomorphan;
75 (SS) Phenoperidine;
76 (TT) Piritramide;
77 (UU) Proheptazine;
78 (VV) Properidine;
79 (WW) Propiram;
80 (XX) Racemoramide;
81 (YY) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide;
82 (ZZ) Tilidine;
83 (AAA) Trimeperidine;
84 (BBB) 3-methylfentanyl, including the optical and geometric isomers
85 (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]- N-phenylpropanamide); and
86 (CCC) 3-methylthiofentanyl
87 (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide).
88 (ii) Unless specifically excepted or unless listed in another schedule, any of the following
89 opium derivatives, their salts, isomers, and salts of isomers when the existence of the salts,

90 isomers, and salts of isomers is possible within the specific chemical designation:
91 (A) Acetorphine;
92 (B) Acetyldihydrocodeine;
93 (C) Benzylmorphine;
94 (D) Codeine methylbromide;
95 (E) Codeine-N-Oxide;
96 (F) Cyprenorphine;
97 (G) Desomorphine;
98 (H) Dihydromorphine;
99 (I) Drotebanol;
100 (J) Etorphine (except hydrochloride salt);
101 (K) Heroin;
102 (L) Hydromorphinol;
103 (M) Methyldesorphine;
104 (N) Methylhydromorphine;
105 (O) Morphine methylbromide;
106 (P) Morphine methylsulfonate;
107 (Q) Morphine-N-Oxide;
108 (R) Myrophine;
109 (S) Nicocodeine;
110 (T) Nicomorphine;
111 (U) Normorphine;
112 (V) Pholcodine; and
113 (W) Thebacon.
114 (iii) Unless specifically excepted or unless listed in another schedule, any material,
115 compound, mixture, or preparation which contains any quantity of the following hallucinogenic
116 substances, or which contains any of their salts, isomers, and salts of isomers when the existence
117 of the salts, isomers, and salts of isomers is possible within the specific chemical designation; as
118 used in this Subsection (2)(iii) only, "isomer" includes the optical, position, and geometric isomers:
119 (A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase;
120 .-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; .-ET; and AET;

121 (B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names:
122 4-bromo-2,5-dimethoxy-.-methylphenethylamine; 4-bromo-2,5-DMA;
123 (C) 4-bromo-2,5-dimethoxypenethylamine, some trade or other names:
124 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 2C-B, Nexus;
125 (D) 2,5-dimethoxyamphetamine, some trade or other names:
126 2,5-dimethoxy-.-methylphenethylamine; 2,5-DMA;
127 (E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;
128 (F) 4-methoxyamphetamine, some trade or other names:
129 4-methoxy-.-methylphenethylamine; paramethoxyamphetamine, PMA;
130 (G) 5-methoxy-3,4-methylenedioxyamphetamine;
131 (H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names:
132 4-methyl-2,5-dimethoxy-.-methylphenethylamine; "DOM"; and "STP";
133 (I) 3,4-methylenedioxy amphetamine;
134 (J) 3,4-methylenedioxymethamphetamine (MDMA);
135 (K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-
136 alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA;
137 (L) N-hydroxy-3,4-methylenedioxyamphetamine, also known as
138 N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;
139 (M) 3,4,5-trimethoxy amphetamine;
140 (N) Bufotenine, some trade and other names: 3-(. -Dimethylaminoethyl)-5-hydroxyindole;
141 3-(2-dimethylaminoethyl)-5-indolol; N, N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine;
142 mappine;
143 (O) Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;
144 (P) Dimethyltryptamine, some trade or other names: DMT;
145 (Q) Ibogaine, some trade and other names:
146 7-Ethyl-6,6.,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2] azepino
147 [5,4-b] indole; Tabernanthe iboga;
148 (R) Lysergic acid diethylamide;
149 (S) Marijuana;
150 (T) Mescaline;
151 (U) Parahexyl, some trade or other names:

152 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl;
153 (V) Peyote, meaning all parts of the plant presently classified botanically as Lophophora
154 williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part of such
155 plant, and every compound, manufacture, salts, derivative, mixture, or preparation of such plant,
156 its seeds or extracts (Interprets 21 USC 812(c), Schedule I(c) (12));
157 (W) N-ethyl-3-piperidyl benzilate;
158 (X) N-methyl-3-piperidyl benzilate;
159 (Y) Psilocybin;
160 (Z) Psilocyn;
161 (AA) Tetrahydrocannabinols, synthetic equivalents of the substances contained in the
162 plant, or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives, and
163 their isomers with similar chemical structure and pharmacological activity such as the following:
164 .1 cis or trans tetrahydrocannabinol, and their optical isomers .6 cis or trans
165 tetrahydrocannabinol, and their optical isomers .3,4 cis or trans tetrahydrocannabinol, and its
166 optical isomers, and since nomenclature of these substances is not internationally standardized,
167 compounds of these structures, regardless of numerical designation of atomic positions covered;
168 (BB) Ethylamine analog of phencyclidine, some trade or other names:
169 N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine,
170 N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;
171 (CC) Pyrrolidine analog of phencyclidine, some trade or other names:
172 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;
173 (DD) Thiophene analog of phencyclidine, some trade or other names:
174 1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP; and
175 (EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.
176 (iv) Unless specifically excepted or unless listed in another schedule, any material
177 compound, mixture, or preparation which contains any quantity of the following substances having
178 a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers
179 when the existence of the salts, isomers, and salts of isomers is possible within the specific
180 chemical designation:
181 (A) Flunitrazepam, trade name Rohypnol;
182 [(A)] (B) Mecloqualone; and

183 [(B)] (C) Methaqualone.
184 (v) Any material, compound, mixture, or preparation containing any quantity of the
185 following substances having a stimulant effect on the central nervous system, including their salts,
186 isomers, and salts of isomers:
187 (A) Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or
188 4,5-dihydro-5-phenyl-2-oxazolamine;
189 (B) Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone,
190 alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;
191 (C) Fenethylline;
192 (D) Methcathinone, some other names: 2-(methylamino)-propiophenone;
193 alpha-(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one;
194 alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone;
195 methylcathinone; AL-464; AL-422; AL-463 and UR1432, its salts, optical isomers, and salts of
196 optical isomers;
197 (E) (.)cis-4-methylaminorex ((.)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
198 (F) N-ethylamphetamine; and
199 (G) N,N-dimethylamphetamine, also known as N,N-alpha-trimethyl-benzeneethanamine;
200 N,N-alpha-trimethylphenethylamine.
201 (vi) Any material, compound, mixture, or preparation which contains any quantity of the
202 following substances, including their optical isomers, salts, and salts of isomers, subject to
203 temporary emergency scheduling:
204 (A) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and
205 (B) N-[1- (2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).
206 (vii) (A) Unless specifically excepted or unless listed in another schedule, any material,
207 compound, mixture, or preparation which contains any quantity of gamma hydro butyrate or its
208 analogs gamma butyrolactone and 1,4 butanediol.
209 (B) As used in this Subsection 58-37-4 (a)(vii), the analog gamma butyrolactone includes
210 butyrolactone, 1,2 butanolide, 2-oxanolone, tetrahydro-2-furanone, dihydro-2(3H)-furanone and
211 tetramethylene glycol, but does not include gamma aminobutric acid.
212 (b) Schedule II:
213 (i) Unless specifically excepted or unless listed in another schedule, any of the following

214 substances whether produced directly or indirectly by extraction from substances of vegetable
215 origin, or independently by means of chemical synthesis, or by a combination of extraction and
216 chemical synthesis:
217 (A) Opium and opiate, and any salt, compound, derivative, or preparation of opium or
218 opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone,
219 and their respective salts, but including:
220 (I) Raw opium;
221 (II) Opium extracts;
222 (III) Opium fluid;
223 (IV) Powdered opium;
224 (V) Granulated opium;
225 (VI) Tincture of opium;
226 (VII) Codeine;
227 (VIII) Ethylmorphine;
228 (IX) Etorphine hydrochloride;
229 (X) Hydrocodone;
230 (XI) Hydromorphone;
231 (XII) Metopon;
232 (XIII) Morphine;
233 (XIV) Oxycodone;
234 (XV) Oxymorphone; and
235 (XVI) Thebaine;
236 (B) Any salt, compound, derivative, or preparation which is chemically equivalent or
237 identical with any of the substances referred to in Subsection (2)(b)(i)(A), except that these
238 substances may not include the isoquinoline alkaloids of opium;
239 (C) Opium poppy and poppy straw;
240 (D) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any
241 salt, compound, derivative, or preparation which is chemically equivalent or identical with any of
242 these substances, and includes cocaine and ecgonine, their salts, isomers, derivatives, and salts of
243 isomers and derivatives, whether derived from the coca plant or synthetically produced, except the
244 substances may not include decocainized coca leaves or extraction of coca leaves, which

245 extractions do not contain cocaine or ecgonine; and
246 (E) Concentrate of poppy straw, which means the crude extract of poppy straw in either
247 liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium poppy.
248 (ii) Unless specifically excepted or unless listed in another schedule, any of the following
249 opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when
250 the existence of the isomers, esters, ethers, and salts is possible within the specific chemical
251 designation, except dextrorphan and levopropoxyphene:
252 (A) Alfentanil;
253 (B) Alphaprodine;
254 (C) Anileridine;
255 (D) Bezitramide;
256 (E) Bulk dextropropoxyphene (nondosage forms);
257 (F) Carfentanil;
258 (G) Dihydrocodeine;
259 (H) Diphenoxylate;
260 (I) Fentanyl;
261 (J) Isomethadone;
262 (K) Levo-alphacetylmethadol, some other names: levo-alpha-acetylmethadol,
263 levomethadyl acetate, or LAAM;
264 (L) Levomethorphan;
265 (M) Levorphanol;
266 (N) Metazocine;
267 (O) Methadone;
268 (P) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
269 (Q) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic
270 acid;
271 (R) Pethidine (meperidine);
272 (S) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
273 (T) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
274 (U) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
275 (V) Phenazocine;

276 (W) Piminodine;
277 (X) Racemethorphan;
278 (Y) Racemorphan;
279 (Z) Remifentanil; and
280 (AA) Sufentanil.
281 (iii) Unless specifically excepted or unless listed in another schedule, any material,
282 compound, mixture, or preparation which contains any quantity of the following substances having
283 a stimulant effect on the central nervous system:
284 (A) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
285 (B) Methamphetamine, its salts, isomers, and salts of its isomers;
286 (C) Phenmetrazine and its salts; and
287 (D) Methylphenidate.
288 (iv) Unless specifically excepted or unless listed in another schedule, any material,
289 compound, mixture, or preparation which contains any quantity of the following substances having
290 a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers
291 when the existence of the salts, isomers, and salts of isomers is possible within the specific
292 chemical designation:
293 (A) Amobarbital;
294 (B) Glutethimide;
295 (C) Pentobarbital;
296 (D) Phencyclidine;
297 (E) Phencyclidine immediate precursors: 1-phenylcyclohexylamine and
298 1-piperidinocyclohexanecarbonitrile (PCC); and
299 (F) Secobarbital.
300 (v) Unless specifically excepted or unless listed in another schedule, any material,
301 compound, mixture, or preparation which contains any quantity of Phenylacetone.
302 Some of these substances may be known by trade or other names: phenyl-2-propanone,
303 P2P; benzyl methyl ketone, methyl benzyl ketone.
304 (vi) (A) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in
305 a U.S. Food and Drug Administration approved drug product, some other names for dronabinol:
306 (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or

307 (-)-delta-9-(trans)-tetrahydrocannabinol; and
308 (B) Nabilone, another name for nabilone:
309 (.)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,
310 6-dimethyl-9H-dibenzo[b,d]pyran-9-one.
311 (c) Schedule III:
312 (i) Unless specifically excepted or unless listed in another schedule, any material,
313 compound, mixture, or preparation which contains any quantity of the following substances having
314 a stimulant effect on the central nervous system, including its salts, isomers whether optical,
315 position, or geometric, and salts of the isomers when the existence of the salts, isomers, and salts
316 of isomers is possible within the specific chemical designation:
317 (A) Those compounds, mixtures, or preparations in dosage unit form containing any
318 stimulant substances listed in Schedule II, which compounds, mixtures, or preparations were listed
319 on August 25, 1971, as excepted compounds under Section 1308.32 of Title 21 of the Code of
320 Federal Regulations, and any other drug of the quantitive composition shown in that list for those
321 drugs or which is the same except that it contains a lesser quantity of controlled substances;
322 (B) Benzphetamine;
323 (C) Chlorphentermine;
324 (D) Clortermine; and
325 (E) Phendimetrazine.
326 (ii) Unless specifically excepted or unless listed in another schedule, any material,
327 compound, mixture, or preparation which contains any quantity of the following substances having
328 a depressant effect on the central nervous system:
329 (A) Any compound, mixture, or preparation containing amobarbital, secobarbital,
330 pentobarbital, or any salt of any of them, and one or more other active medicinal ingredients which
331 are not listed in any schedule;
332 (B) Any suppository dosage form containing amobarbital, secobarbital, or pentobarbital,
333 or any salt of any of these drugs which is approved by the Food and Drug Administration for
334 marketing only as a suppository;
335 (C) Any substance which contains any quantity of a derivative of barbituric acid or any salt
336 of any of them;
337 (D) Chlorhexadol;

338 (E) Ketamine;
339 [(E)] (F) Lysergic acid;
340 [(F)] (G) Lysergic acid amide;
341 [(G)] (H) Methyprylon;
342 [(H)] (I) Sulfondiethylmethane;
343 [(I)] (J) Sulfonethylmethane;
344 [(J)] (K) Sulfonmethane; and
345 [(K)] (L) Tiletamine and zolazepam or any of their salts, some trade or other names for
346 a tiletamine-zolazepam combination product: Telazol, some trade or other names for tiletamine:
347 2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade or other names for zolazepam:
348 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one,
349 flupyrazapon.
350 (iii) Nalorphine.
351 (iv) Unless specifically excepted or unless listed in another schedule, any material,
352 compound, mixture, or preparation containing limited quantities of any of the following narcotic
353 drugs, or their salts calculated as the free anhydrous base or alkaloid:
354 (A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams
355 per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;
356 (B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams
357 per dosage unit, with one or more active non-narcotic ingredients in recognized therapeutic
358 amounts;
359 (C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more
360 than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid
361 of opium;
362 (D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more
363 than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in
364 recognized therapeutic amounts;
365 (E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90
366 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized
367 therapeutic amounts;
368 (F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than

369 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized
370 therapeutic amounts;
371 (G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not
372 more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in
373 recognized therapeutic amounts;
374 (H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with
375 one or more active, non-narcotic ingredients in recognized therapeutic amounts.
376 (v) Unless specifically excepted or unless listed in another schedule, anabolic steroids
377 including any of the following or any isomer, ester, salt, or derivative of the following that
378 promotes muscle growth:
379 (A) Boldenone;
380 (B) Chlorotestosterone (4-chlortestosterone);
381 (C) Clostebol;
382 (D) Dehydrochlormethyltestosterone;
383 (E) Dihydrotestosterone (4-dihydrotestosterone);
384 (F) Drostanolone;
385 (G) Ethylestrenol;
386 (H) Fluoxymesterone;
387 (I) Formebulone (formebolone);
388 (J) Mesterolone;
389 (K) Methandienone;
390 (L) Methandranone;
391 (M) Methandriol;
392 (N) Methandrostenolone;
393 (O) Methenolone;
394 (P) Methyltestosterone;
395 (Q) Mibolerone;
396 (R) Nandrolone;
397 (S) Norethandrolone;
398 (T) Oxandrolone;
399 (U) Oxymesterone;

400 (V) Oxymetholone;
401 (W) Stanolone;
402 (X) Stanozolol;
403 (Y) Testolactone;
404 (Z) Testosterone; and
405 (AA) Trenbolone.
406 Anabolic steroids expressly intended for administration through implants to cattle or other
407 nonhuman species, and approved by the Secretary of Health and Human Services for use, may not
408 be classified as a controlled substance.
409 (d) Schedule IV:
410 (i) Unless specifically excepted or unless listed in another schedule, any material,
411 compound, mixture, or preparation containing not more than 1 milligram of difenoxin and not less
412 than 25 micrograms of atropine sulfate per dosage unit, or any salts of any of them;
413 (ii) Unless specifically excepted or unless listed in another schedule, any material,
414 compound, mixture, or preparation which contains any quantity of the following substances,
415 including its salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts
416 of isomers is possible within the specific chemical designation:
417 (A) Alprazolam;
418 (B) Barbital;
419 (C) Bromazepam;
420 (D) Butorphanol;
421 (E) Camazepam;
422 (F) Chloral betaine;
423 (G) Chloral hydrate;
424 (H) Chlordiazepoxide;
425 (I) Clobazam;
426 (J) Clonazepam;
427 (K) Clorazepate;
428 (L) Clotiazepam;
429 (M) Cloxazolam;
430 (N) Delorazepam;

431 (O) Diazepam;
432 (P) Estazolam;
433 (Q) Ethchlorvynol;
434 (R) Ethinamate;
435 (S) Ethyl loflazepate;
436 (T) Fludiazepam;
437 [(U) Flunitrazepam;]
438 [(V)] (U) Flurazepam;
439 [(W)] (V) Halazepam;
440 [(X)] (W) Haloxazolam;
441 [(Y)] (X) Ketazolam;
442 [(Z)] (Y) Loprazolam;
443 [(AA)] (Z) Lorazepam;
444 [(BB)] (AA) Lormetazepam;
445 [(CC)] (BB) Mebutamate;
446 [(DD)] (CC) Medazepam;
447 [(EE)] (DD) Meprobamate;
448 [(FF)] (EE) Methohexital;
449 [(GG)] (FF) Methylphenobarbital (mephobarbital);
450 [(HH)] (GG) Midazolam;
451 [(II)] (HH) Nimetazepam;
452 [(JJ)] (II) Nitrazepam;
453 [(KK)] (JJ) Nordiazepam;
454 [(LL)] (KK) Oxazepam;
455 [(MM)] (LL) Oxazolam;
456 [(NN)] (MM) Paraldehyde;
457 [(OO)] (NN) Pentazocine;
458 [(PP)] (OO) Petrichloral;
459 [(QQ)] (PP) Phenobarbital;
460 [(RR)] (QQ) Pinazepam;
461 [(SS)] (RR) Prazepam;

462 [(TT)] (SS) Quazepam;
463 [(UU)] (TT) Temazepam;
464 [(VV)] (UU) Tetrazepam;
465 [(WW)] (VV) Triazolam; and
466 [(XX)] (WW) Zolpidem.
467 (iii) Any material, compound, mixture, or preparation of fenfluramine which contains any
468 quantity of the following substances, including its salts, isomers whether optical, position, or
469 geometric, and salts of the isomers when the existence of the salts, isomers, and salts of isomers
470 is possible.
471 (iv) Unless specifically excepted or unless listed in another schedule, any material,
472 compound, mixture, or preparation which contains any quantity of the following substances having
473 a stimulant effect on the central nervous system, including its salts, isomers whether optical,
474 position, or geometric isomers, and salts of the isomers when the existence of the salts, isomers,
475 and salts of isomers is possible within the specific chemical designation:
476 (A) Cathine ((+)-norpseudoephedrine);
477 (B) Diethylpropion;
478 (C) Fencamfamine;
479 (D) Fenproprex;
480 (E) Mazindol;
481 (F) Mefenorex;
482 (G) Pemoline, including organometallic complexes and chelates thereof;
483 (H) Phentermine;
484 (I) Pipradrol; and
485 (J)SPA ((-)-1-dimethylamino-1,2-diphenylethane).
486 (v) Unless specifically excepted or unless listed in another schedule, any material,
487 compound, mixture, or preparation which contains any quantity of dextropropoxyphene
488 (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane), including its salts.
489 (e) Schedule V: Any compound, mixture, or preparation containing any of the following
490 limited quantities of narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid,
491 which includes one or more non-narcotic active medicinal ingredients in sufficient proportion to
492 confer upon the compound, mixture, or preparation valuable medicinal qualities other than those

493 possessed by the narcotic drug alone:
494 (i) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
495 (ii) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams;
496 (iii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams;
497 (iv) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of
498 atropine sulfate per dosage unit;
499 (v) not more than 100 milligrams of opium per 100 milliliters or per 100 grams;
500 (vi) not more than 0.5 milligram of difenoxin and not less than 25 micrograms of atropine
501 sulfate per dosage unit;
502 (vii) unless specifically exempted or excluded or unless listed in another schedule, any
503 material, compound, mixture, or preparation which contains Pyrovalerone having a stimulant effect
504 on the central nervous system, including its salts, isomers, and salts of isomers; and
505 (viii) unless specifically excepted or unless listed in another schedule, any material,
506 compound, mixture, or preparation containing any Buprenorphine and its salts.




Legislative Review Note
as of 12-3-99 2:19 PM

A limited legal review of this legislation raises no obvious constitutional or statutory concerns.

Office of Legislative Research and General Counsel